Vol.
37
No.
7
July 25, 2014Jul 25, 2014
Free

Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial

IDMC Halts Mekinist-Tafinlar Trial Early Due to OS Benefit; Recommends Crossover

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

Volasertib and LDAC Doubled Response in Older Patients

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

Study: Negative HPV Test More Accurate than Negative Pap Test In Predicting Cervical Cancer Risk

Phase II Study: Proton Therapy Can Have Similar Success Rate, Smaller Level of Risk in Treatment of Hodgkin Lymphoma

NCI CTEP-Approved Trials For the Month of July

Zydelig Tablets Approved For Three Blood Cancers

Login